LINE-1 in cancer
LINE-1 is active in roughly 40% of cancers and is linked to faster progression and treatment resistance - but it is only one factor in a heterogenous disease
Cancer is difficult to treat for two main reasons: therapies must kill cancer cells while sparing healthy tissue, and tumors can evolve resistance over time. Even with progress in treatments, many tumors still do not respond or eventually return
LINE-1 is a virus-like genetic element that is usually silenced in healthy adult tissues but can become active in stressed or diseased cells, including about 40% of cancers
LINE-1 is most active in gastrointestinal cancers (esophageal, colorectal, stomach), lung cancer, head and neck cancer, uterine cancer, and ovarian cancer
In cancer cells, LINE-1 can promote resistance to treatment and disease progression by directly inserting into cancer and drug-resistance genes. However, this is only in a minority of cases. More broadly, LINE-1's activity is associated with poor outcomes and faster progression of disease. Unlike cancer genes, which typically have two copies in the genome, LINE-1 has about 100 copies that can be reactivated. Cancer is highly heterogenous, and LINE-1 is one contributing factor; association does not mean causation
Although preclinical models of gastrointestinal cancers suggest that inhibiting LINE-1 could slow the progression of disease, it is unlikely to lead to profound changes in disease trajectory. It is also technically challenging to identify patients with LINE-1-active tumors. Whole genome sequencing technology is enabling the identification of which patients are most likely to respond to LINE-1 inhibition. LINE-1 is one piece of the puzzle in cancer
Have a question about this piece, or a collaboration in mind? Get in touch